This page contains real world evidence. This is a real patient with eosinophilic asthma, compensated by GSK for his time.
The right treatment for the right patient

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older¹

This page contains real world evidence. This is a fictional patient for demonstration purposes. The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in pre-filled pen, pre-filled syringe or as a lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC once every 4 weeks regardless of weight, and is available as a lyophilised powder. The pre-filled formulations are not indicated in 6-11 year olds.¹

This page contains real world evidence. This is a fictional patient for demonstration purposes. The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in pre-filled pen, pre-filled syringe or as a lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC once every 4 weeks regardless of weight, and is available as a lyophilised powder. The pre-filled formulations are not indicated in 6-11 year olds.¹

Are your patients eligible for Nucala?

Nice Guidance

*All Wales Medicines Strategy Group refer to the NICE TA671, therefore adopt the criteria set out in the NICE guidance.3

SMC Guidance

The right treatment for the right patient

Find out more below about the types of patients who could benefit from Nucala.

50 years old

"I'm really worried that I'll have another asthma attack - what if it happens in the pool?"

  • Asthma diagnosis 15 years ago
  • 4 exacerbations in the past year
  • Eosinophil count: 400 cells/μL
  • Total IgE: 140kU/L
  • Maintenance ICS/LABA, 2 puffs BD
  • FEV1 % predicted: 62%
Nucala Identifying Patient

Fictional patient profile for illustrative purposes.

Find out how Nucala could reduce exacerbations in your patients

Nucala reduced the rate of exacerbations by 53% compared to placebo at 32 weeks in the MENSA study (Primary endpoint: 0.83/year (n=194) vs. 1.74/year (n=191) (95% CI: 36–65) p<0.001)5

47 years old

"I'm worried about the side effects of steroids - I've already gained weight."

  • Asthma diagnosis 7 years ago
  • 2 exacerbations last year
  • Eosinophil count: 300 cells/μL
  • Total IgE: 114kU/L
  • Maintenance OCS
  • FEV1 % predicted: 58%
  • High-dose maintenance ICS/LABA, 2 puffs BD
Nucala Identifying Patient

Fictional patient profile for illustrative purposes.

Explore how Nucala could allow your patients to reduce their OCS dose

52% reduction in median maintenance OCS dose. (n=143) (95% CI: 50–75) p<0.001. 10mg at baseline vs. 5mg at 12 months. 52% is the median percent reduction from baseline in average daily dose of maintenance OCS. Results are descriptive.

10 years old

"I hate that I can't play outside with my friends because my mum is worried about my asthma attacks."

  • Asthma diagnosis 5 years ago
  • 4 exacerbations in the past year, one leading to an ED visit
  • Eosinophil count: 340 cells/μL
  • Total IgE: 148kU/L
  • FEV1 % predicted: 65%
  • High paediatric dose ICS/LABA, 2 puffs BD
Nucala Identifying Patient

Fictional patient profile for illustrative purposes.

Nucala is the first and only biologic indicated from age 6¹

The licensed dose of NUCALA in children aged 6–11 years is 40mg SC once every 4 weeks, regardless of weight.¹

Footnotes

An exacerbation is defined as deterioration in asthma requiring use of systemic corticosteroids and/or an ED visit and/or hospital admission.

Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. These limitations are important when interpreting results: lack of comparator arm, differences in patient populations and data collection vs. randomised controlled trials.6

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.¹

Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3% respectively, n=385) which occurred mainly within the first 3 injections.¹ The long-term safety and immunogenicity profile of Nucala was similar to that observed in placebo-controlled asthma trials.7

The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, pre-filled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6–11 years is 40mg once every 4 weeks, regardless of weight and available in lyophilised powder. The pre-filled formualations are not indicated in 6-11 year olds.¹

BD, twice daily; ED, emergency department; IgE, immunoglobulin E; IL, interleukin; NICE, The National Institute for Health and Care Excellence; OCS, oral corticosteroid; SC, subcutaneous; SMC, Scottish Medicine Consortium.

References

  1. Nucala SmPC, 2020
  2. NICE - Final Appraisal Document Mepolizumab for SEA Dec 2020
  3. All Wales Medicines Strategy Group Medicines appraisals and guidance for mepolizumab. https://awmsg.nhs.wales/medicines-appraisals-and-guidance/medicines-appraisals/mepolizumab-nucala/ (last accessed Jan 2021).
  4. SMC - Scottish Medicines Consortium (1149/16 June 2016)
  5. Ortega HG et al. N Engl J Med 2014; 371:1198-1207
  6. Leather DA et al. Adv Ther 2020;1-21
  7. Khurana S et al. Clin Ther 2019; 41:2041-2056

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2021 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

PM-GB-MPL-WCNT-200027 v2 | February 2021